Literature DB >> 29393747

Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.

Olga V Friese1, Jacquelynn N Smith1, Paul W Brown1, Jason C Rouse2.   

Abstract

Antibody-drug conjugation strategies are continuously evolving as researchers work to improve the safety and efficacy of the molecules. However, as a part of process and product development, confirmation of the resulting innovative structures requires new, specialized mass spectrometry (MS) approaches and methods, as compared to those already established for antibody-drug conjugates (ADCs) and the heightened characterization practices used for monoclonal antibodies (mAbs), in order to accurately elucidate the resulting conjugate forms, which can sometimes have labile chemical bonds and more extreme chemical properties like hydrophobic patches. Here, we discuss practical approaches for characterization of ADCs using new methodologies and ultrahigh-resolution MS, and provide specific examples of these approaches. Denaturing conditions of typical liquid chromatography (LC)/MS analyses impede the successful detection of intact, 4-chain ADCs generated via cysteine site-directed chemistry approaches where hinge region disulfide bonds are partially reduced. However, this class of ADCs is detected intact reliably under non-denaturing size-exclusion chromatography/MS conditions, also referred to as native MS. For ADCs with acid labile linkers such as one used for conjugation of calicheamicin, careful selection of mobile phase composition is critical to the retention of intact linker-payload during LC/MS analysis. Increasing the pH of the mobile phase prevented cleavage of a labile bond in the linker moiety, and resulted in retention of the intact linker-payload. In-source fragmentation also was observed with typical electrospray ionization (ESI) source parameters during intact ADC mass analysis for a particular surface-accessible linker-payload moiety conjugated to the heavy chain C-terminal tag, LLQGA (via transglutaminase chemistry). Optimization of additional ESI source parameters such as cone voltages, gas pressures and ion transfer parameters led to minimal fragmentation and optimal sensitivity. Ultrahigh-resolution (UHR) MS, combined with reversed phase-ultrahigh performance (RP-UHP)LC and use of the FabRICATOR® enzyme, provides a highly resolving, antibody subunit-domain mapping method that allows rapid confirmation of integrity and the extent of conjugation. For some ADCs, the hydrophobic nature of the linker-payload hinders chromatographic separation of the modified subunit/domains or causes very late elution/poor recovery. As an alternative to the traditionally used C4 UHPLC column chemistry, a diphenyl column resulted in the complete recovery of modified subunit/domains. For ADCs based on maleimide chemistry, control of pH during proteolytic digestion is critical to minimize ring-opening. The optimum pH to balance digestion efficiency and one that does not cause ring opening needed to be established for successful peptide mapping.

Entities:  

Keywords:  ADC; Heightened characterization; Intact mass; Mass spectrometry; Subunit domain

Mesh:

Substances:

Year:  2018        PMID: 29393747      PMCID: PMC5916563          DOI: 10.1080/19420862.2018.1433973

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  23 in total

Review 1.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Authors:  Laurent Ducry; Bernhard Stump
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

2.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

Authors:  Pavel Strop; Shu-Hui Liu; Magdalena Dorywalska; Kathy Delaria; Russell G Dushin; Thomas-Toan Tran; Wei-Hsien Ho; Santiago Farias; Meritxell Galindo Casas; Yasmina Abdiche; Dahui Zhou; Ramalakshmi Chandrasekaran; Caroline Samain; Carole Loo; Andrea Rossi; Mathias Rickert; Stellanie Krimm; Teresa Wong; Sherman Michael Chin; Jessica Yu; Jeanette Dilley; Javier Chaparro-Riggers; Gary F Filzen; Christopher J O'Donnell; Fang Wang; Jeremy S Myers; Jaume Pons; David L Shelton; Arvind Rajpal
Journal:  Chem Biol       Date:  2013-02-21

3.  Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues.

Authors:  John F Valliere-Douglass; William A McFee; Oscar Salas-Solano
Journal:  Anal Chem       Date:  2012-03-02       Impact factor: 6.986

4.  Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.

Authors:  François Debaene; Amandine Boeuf; Elsa Wagner-Rousset; Olivier Colas; Daniel Ayoub; Nathalie Corvaïa; Alain Van Dorsselaer; Alain Beck; Sarah Cianférani
Journal:  Anal Chem       Date:  2014-10-21       Impact factor: 6.986

Review 5.  Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.

Authors:  Richard Y-C Huang; Guodong Chen
Journal:  Drug Discov Today       Date:  2016-04-11       Impact factor: 7.851

6.  Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I - Optimization of separation conditions.

Authors:  Morgan Sarrut; Amélie Corgier; Szabolcs Fekete; Davy Guillarme; David Lascoux; Marie-Claire Janin-Bussat; Alain Beck; Sabine Heinisch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-06-28       Impact factor: 3.205

7.  A rapid approach for characterization of thiol-conjugated antibody-drug conjugates and calculation of drug-antibody ratio by liquid chromatography mass spectrometry.

Authors:  David Firth; Leonard Bell; Martin Squires; Sian Estdale; Colin McKee
Journal:  Anal Biochem       Date:  2015-06-09       Impact factor: 3.365

8.  Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.

Authors:  Patrick Dennler; Aristeidis Chiotellis; Eliane Fischer; Delphine Brégeon; Christian Belmant; Laurent Gauthier; Florence Lhospice; François Romagne; Roger Schibli
Journal:  Bioconjug Chem       Date:  2014-02-12       Impact factor: 4.774

9.  Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Jagath R Junutula; Kelly M Flagella; Richard A Graham; Kathryn L Parsons; Edward Ha; Helga Raab; Sunil Bhakta; Trung Nguyen; Debra L Dugger; Guangmin Li; Elaine Mai; Gail D Lewis Phillips; Hajime Hiraragi; Reina N Fuji; Jay Tibbitts; Richard Vandlen; Susan D Spencer; Richard H Scheller; Paul Polakis; Mark X Sliwkowski
Journal:  Clin Cancer Res       Date:  2010-08-30       Impact factor: 12.531

10.  A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.

Authors:  Robert E Birdsall; Henry Shion; Frank W Kotch; April Xu; Thomas J Porter; Weibin Chen
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

View more
  6 in total

Review 1.  Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates.

Authors:  Xiaoyu Zhu; Shihan Huo; Chao Xue; Bo An; Jun Qu
Journal:  J Pharm Anal       Date:  2020-05-23

2.  Application of triple quadrupole mass spectrometry for the characterization of antibody-drug conjugates.

Authors:  Malin Källsten; Matthijs Pijnappel; Rafael Hartmann; Fredrik Lehmann; Lucia Kovac; Sara Bergström Lind; Jonas Bergquist
Journal:  Anal Bioanal Chem       Date:  2019-03-08       Impact factor: 4.142

3.  Native size-exclusion chromatography-mass spectrometry: suitability for antibody-drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels.

Authors:  Jay Jones; Laura Pack; Joshua H Hunter; John F Valliere-Douglass
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

4.  State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.

Authors:  Evolène Deslignière; Anthony Ehkirch; Bastiaan L Duivelshof; Hanna Toftevall; Jonathan Sjögren; Davy Guillarme; Valentina D'Atri; Alain Beck; Oscar Hernandez-Alba; Sarah Cianférani
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

5.  High sensitivity LC-MS profiling of antibody-drug conjugates with difluoroacetic acid ion pairing.

Authors:  Jennifer M Nguyen; Jacquelynn Smith; Susan Rzewuski; Cristina Legido-Quigley; Matthew A Lauber
Journal:  MAbs       Date:  2019-09-10       Impact factor: 5.857

6.  Targeting cancer with antibody-drug conjugates: Promises and challenges.

Authors:  Alexis Q Dean; Shen Luo; Julianne D Twomey; Baolin Zhang
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.